Currently, laparoscopic sacrocolpopexy is considered the gold standard for pelvic organ prolapse (POP) surgery.1 Several alternative techniques have been described using different anatomical references such as the ileo-pectine ligament,2,3 the round ligament4, or the external oblique muscle aponeurosis.5
The U.S. Food and Drug Administration approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer.
The FDA has announced it has granted approval to Myovant Sciences for OrgovyxTM (relugolix) in the treatment of adult patients with advanced prostate cancer. Patients with advanced prostate cancer being treated with androgen deprivation therapy now have a once-daily oral treatment. Orgovyx, an oral therapy, reduce the secretion of the hormone, testosterone, by blocking the […]
Testicular cancer is associated with excellent prognosis and cure is achieved in most patients with advanced cancer treated with cisplatin-based chemotherapy. However, testicular cancer survivors are at increased risk of accelerated atherosclerosis, which significantly contributes to their late morbidity and mortality.
Therapeutic options for treating advanced renal cell cancer (RCC) are rapidly evolving. Vascular endothelial growth factor (VEGF)-directed therapy, predominantly VEGF receptor (VEGFr) tyrosine kinase inhibitors (TKIs) had been the most effective first line treatment since 2005 irrespective of International Metastatic RCC Database Consortium (IMDC) risk stratification.
Studies assessing outcome improvements over a long period according to systemic therapy strategies for metastatic renal cell carcinoma using real-world data, including the results of the recent era of immune checkpoint inhibitors, are limited.
The objective of this study was to evaluate geographical and temporal variations in prostate cancer incidence in Victoria, Australia. This study analysed 105,349 cases of incident prostate cancer between 1982 and 2016 from the population-based Victorian Cancer Registry.
Focal therapy has emerged as a promising treatment option for men with localised prostate cancer. However, most of the evaluation of postoperative function has taken place at a relatively high, non-granular level.
To determine preoperative diagnostic accuracy of F-fluciclovine PET/CT-scan in detection (or exclusion) of lymph node metastases (LNM) in men with prostate cancer (PCa) in comparison to the histopathological results of the extended pelvic lymph node dissection (e-PLND).
The aim was to evaluate the efficacy and safety of abiraterone acetate plus prednisolone in patients with chemotherapy-naïve early metastatic castration-resistant prostate cancer who failed first-line androgen deprivation therapy.
